Telegraph Hill Partners
Venture capitalSan Francisco · Growth–Late Stage · 17 people tracked
Also known as TELEGRAPH HILL PARTNERS MANAGEMENT COMPANY LLC
Investment thesis
Telegraph Hill Partners partners with private life science, medical device, and healthcare companies that have novel technologies, a solid customer base, and innovative management teams. The firm provides growth capital to high-quality companies seeking to build and expand their organizations, offering an experienced team focused on efficiently driving growth and profitability while preserving each company's vision and integrity.
Source: firm website, verified Aug 25, 2026.
Team · 17 people
from the firm's website & curated & public directories
What they invest in
from 26 of 28 portfolio companiesBiotech ×16Healthtech ×13Deep Tech ×8Medical Devices ×7AI & Machine Learning ×5Advanced Manufacturing ×4SaaS ×4Enterprise Software ×3
HQs:United States×19
Investments · 28 tracked
founders shown can be your intro pathBy year:2026 · 12023 · 32022 · 12021 · 22019 · 22017 · 32016 · 12015 · 114 dated
Cell Microsystems develops automated instruments for cellular and molecular workflows used in life science research, including oncology, stem cell biology, and regenerative medicine.
BiotechDeep TechHardwareMedical DevicesDurham, US
Scott McGinnis(President)Nancy Allbritton(Director)Yuli Wang(Director)Matthew Megaro(Director)Gary Pace(Executive Officer, Director)Christopher Sims(Executive Officer, Director)
Board seatDeval LashkariRob Capone· per SEC Form D
Co-investorsIDEA NC
etherFAX provides cloud-based secure document delivery and fax transmission for businesses handling sensitive information.
AI & Machine LearningCloud ComputingCybersecurityEnterprise SoftwareHealthtechSaaS
Paul Banco(Co-Founder and EVP of Federal Programs)Rob Cichielo(Co-Founder and Chief Technology Officer)Jay Volk(Chief Executive Officer)Emil Sturniolo(Chief Security Officer)Allison Kirsch(Chief Marketing Officer)
BiotechAnn Arbor, US
Alberto Elli(Executive Officer, Director)Jack Ball(Executive Officer, Director)
BoardThomas Raffin(Director)in
Board seatDeval LashkariRob Hart· per SEC Form D · $9.8M raise · filed Jun 2017
HealthtechCarlsbad, US
WAYNE WOODARD(Executive Officer, Director)
BoardALEXANDER HERZICK(Director)inRICK HANCOCK(Director)
Board seatDeval LashkariPaul Grossman· per SEC Form D · $10.3M raise · filed Apr 2016
BiotechSan Diego, US
Robert Finzi(Director)David Wellis, Ph.D.(Executive Officer, Director)
BoardAlex Herzik(Director)
Board seatDeval LashkariPaul Grossman· per SEC Form D · $15M raise · filed Nov 2021
HealthtechBloomington, US
Steve Lefar(Director)David McLean(Executive Officer, Director)Ravi Nalliah(Director)Kevin Roche(Executive Officer, Director)
BoardJeanette Welsh(Director)inJ. Matthew Mackowski(Director)
Board seatRob CaponeGary Curtis· per SEC Form D · filed Dec 2022
Invisalert Solutions provides a patient safety platform using machine learning and AI to monitor and prevent adverse events such as falls, infections, and elopement across acute care, emergency departments, behavioral health, and long-term care facilities.
AI & Machine LearningEnterprise SoftwareHealthtechWest Chester, US
Pete Nagy(Executive Officer, Director)Mark Gold(Director)
BoardRegina Widdow(Director)
Board seatRob HartGary CurtisTom Raffin· per SEC Form D
Mosaic Biosciences is a biologics discovery company that advances biologic drug candidates from discovery through IND-enabling studies and clinical development, working with partners across multiple therapeutic modalities.
BiotechDeep TechBoulder, US
Marty (Martin) Stanton(Founder & former CEO)Eric Furfine(Chief Scientific Officer)Alexei Kazantsev(Vice President Protein Design and Engineering)Tracey Mullen(Chief Strategy Officer)Scott Glaser(SVP, Biologics Discovery)Jean-Pierre Wery(Chief Executive Officer)
Board seatJeanette WelshRob Capone· per SEC Form D
A biopharmaceutical company that discovers and develops medicines, building on immunology research to explore additional disease areas.
BiotechHealthtechMadison, US
Jigar Patel(Executive Officer, Director)
Board seatDeval LashkariRob Hart· per SEC Form D
Panome Bio provides metabolomics, proteomics, and multi-omics integration workflows along with a computational platform that analyzes and integrates diverse biological data types.
AI & Machine LearningBiotechDeep TechHealthtechSaint Louis, US
Edward Weinstein(Executive Officer, Director)inTom Cohen(Executive Officer)in
BoardDavid Smoller(Director)inAlexander Herzick(Director)in
Board seatDeval LashkariRob Capone· per SEC Form D
Co-investorsBioGenerator VenturesCultivation Capital
BiotechVancouver
Andrew Booth(Director)Andrew J. Schwab(Director)inR. James Taylor(Executive Officer, Director)Joe Victor(Executive Officer, Director)Euan Ramsay(Executive Officer)Daniel Nixon(Director)
Board seatDeval Lashkari· per SEC Form D · $6M raise · filed Nov 2019
Co-investorsRising Tide5AM Ventures
Seattle, US
Ronald Seubert(Executive Officer, Director, Promoter)Evan Castiglia(Executive Officer)Joseph Victor(Executive Officer, Director)Frank Witney(Director)Eric Kaldjian(Executive Officer)
Board seatRobert Shepler· per SEC Form D · $16.3M raise · filed Aug 2017
Co-investors5AM VenturesArboretum VenturesF-Prime CapitalSofinnova Ventures
Argonaut Manufacturing Solutions develops software for biopharmaceutical manufacturing operations, focusing on fill-finish processes and yield optimization.
Advanced ManufacturingBiotechSaaS
Carterra develops surface plasmon resonance (SPR) platforms for high-throughput biomolecular interaction analysis.
BiotechDeep TechMedical Devices
DYNEX Technologies manufactures fully automated ELISA laboratory systems and diagnostic instruments for clinical and research laboratories.
Medical Devices
Co-investorsAmpersand
Emerging Therapy Solutions provides comprehensive management solutions for cell and gene therapies and transplants to payers, self-insured employers, and secondary payers.
HealthtechInsurTechMedical Devices
David J. McLean
Frontier Psychiatry provides telepsychiatry services for residents of Montana, Idaho, and Alaska, offering psychiatric evaluations, medication management, therapy, and ADHD assessments without requiring referrals.
Digital HealthHealthtechMental HealthMontana, US
Montana psychiatrists
Kytopen develops non-viral gene delivery technology called Flowfect that combines fluid flow with electric fields to deliver payloads such as mRNA, DNA, and CRISPR Cas9 RNP into cells for high-throughput transfection.
BiotechDeep TechHardwareCambridge, US
Cullen Buie(Director)Paulo Garcia(Executive Officer, Director, Promoter)Michael Chiu(Director, Executive Officer)
BoardPaxton Major(Director)Ann DeWitt(Director)inPaul Wotton(Director)
Co-investorsBantam GroupHorizons VenturesMassVenturesSelvedge VentureTBD AngelsThe Engine Ventures+1 more
Nivagen is a specialty pharmaceutical company that develops, manufactures, and markets generic and specialty drugs including sterile injectables and 505(b)(2) products, operating manufacturing facilities in California, Europe, and Japan.
Advanced ManufacturingBiotechHealthtechCalifornia, US
Promptly provides an all-in-one patient experience suite that automates administrative tasks like appointment scheduling, reminders, and payment processing for medical practices.
Enterprise SoftwareHealthtechSaaS
RevMedica develops smart surgical stapling and soft tissue management systems for minimally invasive and robotic procedures, designed to provide real-time intraoperative data and improve clinical decision-making for surgeons.
AI & Machine LearningHealthtechMedical DevicesMiddletown, US
Thomas Wenchell(Chief Executive Officer and Co-Founder)inC. Robert Satti(Director)
Co-investorsConnecticut Innovations
TrakCel provides OCELLOS, a Salesforce-powered cellular orchestration platform for managing cell and gene (advanced) therapy supply chains, giving therapy developers patient-by-patient visibility with full chain-of-identity and chain-of-custody audit trails.
HealthtechLogistics & Supply ChainSaaS
Co-investorsCencora Ventures
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.
Exits · 1
IPOs and acquisitions across the tracked portfolioAkoyabioacq. by Quanterix
Portfolio news
latest coverage across their companiesKytopen · nationaltoday.com · Apr 10, 2026
Public market activity · per SEC filings
what is this? ⓘDisclosed stake · filed Feb 2016
Disclosed stake · filed Jan 2015
Disclosed stake · filed Feb 2014
7 insider ownership filings (Forms 3/4/5)
at Alpha Teknova, Inc. (TKNO)
Files 13F institutional holdings reports · latest Jan 2016
From the firm's own SEC EDGAR filings — stakes and insider roles in public companies, typically portfolio companies after an IPO. Not a portfolio list published by the firm.
Frequently asked questions
- How many investments has Telegraph Hill Partners made?
- Telegraph Hill Partners has 22 tracked investments, 1 of which have exited via acquisition or IPO, including 1 dated in the last 24 months.
- What stage does Telegraph Hill Partners invest at?
- Telegraph Hill Partners invests at the Growth, Late Stage stages.
- What is Telegraph Hill Partners's typical check size?
- Telegraph Hill Partners typically writes checks of $2M – $8M.
- What sectors does Telegraph Hill Partners focus on?
- Telegraph Hill Partners focuses on Biotech, Digital Health, Healthtech, Medical Devices.
- Where is Telegraph Hill Partners located?
- Telegraph Hill Partners is headquartered in San Francisco, US.
- Does Telegraph Hill Partners lead rounds?
- Yes, Telegraph Hill Partners leads investment rounds.
- Who does Telegraph Hill Partners co-invest with?
- Telegraph Hill Partners most often shares deals with aMoon, BioGenerator Ventures, Connecticut Innovations, among 12 tracked co-investors.
Images
Co-investors · 1
5AM Ventures is a life science venture capital firm founded in 2002 that invests primarily in private therapeutic companies, with a focus on biopharmaceuticals, drug delivery technologies, and life science instruments.
Firms observed investing alongside Telegraph Hill Partners, from public investor directories. Shared companies are the overlap with Telegraph Hill Partners's recorded portfolio.
Similar investors
.jpeg){kind=logo}
B Capital is a global investment firm backing early to late-stage technology innovators across technology, healthcare, and energy & resilience sectors.
DCVC (Data Collective) is a deep tech venture capital firm that backs entrepreneurs using computational approaches to solve large-scale real-world problems across many industries.
Eight Roads Ventures is a venture capital firm that backs and partners with technology and healthcare companies.
GV (Google Ventures) is a venture capital firm that has invested in artificial intelligence and machine learning since its early days, building a global portfolio of more than 100 AI companies across infrastructure, life sciences, and applications.
Khosla Ventures is a venture capital firm that invests in early-stage companies focused on technology, mobile, and clean energy sectors, including biotechnology applications. The firm provides capital and strategic support to entrepreneurs developing breakthrough technologies across multiple markets.